A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults
Launched by IPSEN · Apr 14, 2025
Trial Information
Current as of June 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called IPN10200 for adults with Cervical Dystonia (CD), a condition that causes painful and involuntary muscle contractions in the neck, leading to stiffness and discomfort. The trial aims to find out if IPN10200 is effective and safe compared to a placebo, which is a treatment that looks like the real drug but has no active ingredients. Currently, CD is often treated with injections that last about three months, but IPN10200 is designed to provide relief for a longer period.
To participate in this trial, individuals must be diagnosed with isolated Cervical Dystonia and show moderate to severe symptoms. This means they will need to have a certain level of pain and movement issues. Participants will go through a screening process to ensure they qualify and will then take part in a 36-week treatment period, where they may receive either IPN10200 or a placebo. Over the course of the study, participants will have regular visits to the clinic for check-ups, blood tests, and to fill out questionnaires about their experience. The entire study will last up to 40 weeks, which is about 9 months.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- 1. A clinical diagnosis of isolated Cervical Dystonia (CD) (idiopathic) characterized by dystonic symptoms localised to the head, neck, and shoulder areas with at least moderate severity at Screening and Baseline (Day 1) defined as:
- • (a) Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total score ≥20
- • (b) TWSTRS-Severity subscale score ≥15
- • (c) TWSTRS-Disability subscale score ≥3
- • (d) TWSTRS-Pain subscale score ≥ 1
- • 2. Treatment naïve or non-naïve to BoNT therapy for CD
- Exclusion Criteria:
- 1. Participants presenting with a swallowing disorder of any origin which might be exacerbated by BoNT treatment, such as:
- • (a) Grade 3 or 4 on the Dysphagia Severity Scale (severe dysphagia) with swallowing difficulties and requiring a change in diet.
- • 2. Predominant anterocollis.
- • 3. Predominant retrocollis.
- • 4. Traumatic torticollis or tardive torticollis.
- • 5. Marked limitation on passive range of motion that suggests cervical contractures or structural abnormality.
About Ipsen
Ipsen is a global biopharmaceutical group dedicated to innovation and specialty care, focusing on the discovery, development, and commercialization of transformative medicines for patients with serious diseases. With a strong emphasis on oncology, neuroscience, and rare diseases, Ipsen leverages cutting-edge research and advanced technologies to deliver high-quality therapies that address unmet medical needs. Committed to scientific excellence and ethical practices, Ipsen collaborates with healthcare professionals and stakeholders to drive patient-centered solutions and improve health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Ipsen Medical Director
Study Director
Ipsen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported